May 10, 2021, 13:54 PM IST
New Delhi: 2-deoxy-D-glucose (2-DG), the anti-COVID-19 drug that has been developed by Defence Research and Development Organisation (DRDO) and been given an emergency use nod by Drugs Controller General of India s (DCGI), was first studied by Patanjali researchers, claimed Acharya Balkrishna on Sunday (May 9, 2021).
A day after the DCGI granted permission for the Emergency Use of this drug as an adjunct therapy in moderate to severe COVID-19 patients, Acharya Balkrishna said, We take immense pride that Patanjali has been the pioneer centre-stone for most of the researches conducted for COVID-19.
Balkrishna, MD of Patanjali Ayurved Ltd and co-founder of Patanjali Yogpeeth in Haridwar, also shared a picture of his research paper, co-authored with three other researchers.